Format

Send to

Choose Destination
Nat Rev Immunol. 2012 Apr 10;12(5):317-8. doi: 10.1038/nri3192.

The storm has cleared: lessons from the CD28 superagonist TGN1412 trial.

Author information

1
Institute for Virology and Immunobiology, Versbacher Strasse 7, D-97078 Würzburg, Germany. huenig@vim.uni-wuerzburg.de

Abstract

The life-threatening cytokine-release syndrome suffered by six volunteers in a Phase I clinical trial following administration of the CD28 superagonist antibody TGN1412 (developed by TeGenero) in March 2006 was completely unpredicted by the preclinical studies. Here, Thomas Hünig, main founder of TeGenero, describes the recent investigations into what went wrong and discusses the lessons learnt for future clinical trials.

PMID:
22487653
DOI:
10.1038/nri3192
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center